Jeff Cole - Cadrenal Therapeutics, Chief Officer
| CVKD Stock | 14.01 0.49 3.38% |
Executive
Jeff Cole is Chief Officer of Cadrenal Therapeutics, Common
| Address | 822 A1A North, Ponte Vedra, FL, United States, 32082 |
| Phone | 904 300 0701 |
| Web | https://www.cadrenal.com |
Jeff Cole Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeff Cole against Cadrenal Therapeutics, stock is an integral part of due diligence when investing in Cadrenal Therapeutics,. Jeff Cole insider activity provides valuable insight into whether Cadrenal Therapeutics, is net buyers or sellers over its current business cycle. Note, Cadrenal Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cadrenal Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Cadrenal Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.7099) % which means that it has lost $0.7099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2515) %, meaning that it created substantial loss on money invested by shareholders. Cadrenal Therapeutics,'s management efficiency ratios could be used to measure how well Cadrenal Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -1.03. The current year's Return On Capital Employed is expected to grow to -0.94. At present, Cadrenal Therapeutics,'s Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mike Rhee | Senti Biosciences | N/A | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Garth LeesRolfe | Inhibikase Therapeutics | N/A | |
| Michael JD | Foghorn Therapeutics | 59 | |
| Kristian MBA | Foghorn Therapeutics | 48 | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Thomas Chung | Senti Biosciences | N/A | |
| MD MBA | SAB Biotherapeutics | 51 | |
| Bob Lally | Ikena Oncology | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Dee Dragon | Senti Biosciences | N/A | |
Management Performance
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.71 |
Cadrenal Therapeutics, Leadership Team
Elected by the shareholders, the Cadrenal Therapeutics,'s board of directors comprises two types of representatives: Cadrenal Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cadrenal. The board's role is to monitor Cadrenal Therapeutics,'s management team and ensure that shareholders' interests are well served. Cadrenal Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cadrenal Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CoFounder CFO | ||
| Quang Pham, Chairman CEO | ||
| Jeff Cole, Chief Officer | ||
| FACC FAHA, Chief Officer | ||
| Jeffrey Cole, Chief Officer |
Cadrenal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cadrenal Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 18.88 M | ||||
| Shares Outstanding | 1.66 M | ||||
| Shares Owned By Insiders | 34.00 % | ||||
| Number Of Shares Shorted | 39.48 K | ||||
| Price To Book | 6.81 X | ||||
| EBITDA | (8.34 M) | ||||
| Net Income | (8.36 M) | ||||
| Total Debt | 21.35 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.